Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase NA 1Phase EARLY_PHASE1 1

Status

Terminated 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1Lymphoma, Follicular 1Dermatitis, Atopic 1Breast Neoplasms 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Interventional × dupilumab × Clear all
NCT05967884 2023-08-01

PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer

Ottawa Hospital Research Institute

Phase 2 Unknown
20 enrolled
Breast

Breast Neoplasms

NCT03736967 2021-11-01

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Regeneron Pharmaceuticals

Phase 2 Terminated
206 enrolled 34 charts
Lymphoid

Dermatitis, Atopic, Lymphoma, Follicular

NCT03886493 2021-10-15

Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated
7 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡